Evoke Pharma, Inc. Enters into Office Lease Agreement with SB Corporate Centre III-IV, LLC
December 21, 2016 at 09:10 pm
Share
On December 19, 2016, Evoke Pharma, Inc. entered into an Office Lease Agreement with SB Corporate Centre III-IV, LLC (the Landlord) pursuant to which the company leased approximately 3,031 rentable square feet of space from the landlord at 420 Steven Avenue, Suite 370, Solana Beach, CA 92075. The company will use the office space as its new corporate headquarters. The Lease will commence on January 1, 2017 and will expire on December 31, 2018 (the Initial Lease Term), unless earlier terminated, with an option to extend the Initial Lease Term for an additional two years subject to specified prior written notice. The lease provides for, among other things, a monthly base rent during the Initial Lease Term in the amounts set as: for 1-12 months, monthly basic rent was 11,214.70 and 13-24 months, monthly basic rent was 11,551.14. In addition to rent, the company agreed to pay a portion of the taxes and utility, maintenance and other operating costs paid or accrued in connection with the ownership and operation of the property.
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
EVOKE PHARMA, INC. 
